<DOC>
	<DOC>NCT02192294</DOC>
	<brief_summary>This is an open-label, randomized, single-dose, one-cohort, two-sequence, two-period crossover study in healthy subjects.</brief_summary>
	<brief_title>Absolute Bioavailability Of Bosutinib</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subjects (of nonchildbearing potential). Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study. Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, accept placement of indwelling catheter for infusion and other study procedures. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies). A positive urine drug screen for cocaine, tetrahydrocannabinol (THC), opiates/opioids, benzodiazepines and amphetamines.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Bosutinib</keyword>
	<keyword>absolute bioavailability</keyword>
</DOC>